Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

NIAID

- PMLiVE

UK researchers uncover first new asthma and COPD attack treatment in 50 years

The phase 2 study showed that benralizumab could be re-purposed for use in emergency settings

- PMLiVE

Seven strategic steps to enhance patient recruitment & retention in your influenza studies

The development of all treatments, including vaccines, is dependent on people taking part in clinical trials but this can be challenging for influenza studies, especially given the typically short patient...

Innovative Trials

- PMLiVE

AstraZeneca announces positive results for Truqap in phase 3 prostate cancer study

More than 52,000 cases of prostate cancer are diagnosed in the UK every year

- PMLiVE

AstraZeneca announces $3.5bn US investment to boost research and manufacturing

The commitment is part of the company’s ambition to achieve $80bn in total revenue by 2030

- PMLiVE

AstraZeneca/Merck’s Koselugo shows promise in adults with neurofibromatosis type 1

The rare genetic condition affects an estimated 1.7 million people globally

- PMLiVE

Novavax announces FDA clinical hold lift on phase 3 COVID-19/flu vaccine study

The serious adverse event reported was found to be unrelated to the vaccine

Daiichi Sankyo logo

Daiichi Sankyo enters $300m licensing deal with Alteogen to develop subcutaneous Enhertu

The company will use Alteogen’s hybrozyme technology to advance the formulation

- PMLiVE

AstraZeneca/Amgen’s Tezspire shows promise in phase 3 CRSwNP trial

The severe asthma drug met both of the late-stage study’s co-primary endpoints

- PMLiVE

AstraZeneca’s Fasenra approved by EC to treat rare inflammatory disease EGPA

Eosinophilic granulomatosis with polyangiitis affects approximately 118,000 people globally

- PMLiVE

AstraZeneca’s Voydeya recommended by NICE to treat rare blood disorder PNH

The drug has been recommended for use alongside the company’s C5 inhibitors

- PMLiVE

AstraZeneca/Ionis’ Wainzua receives positive CHMP opinion to treat rare disease ATTRv-PN

The drug can be self-administered via an auto-injector and is designed to lower the production of TTR protein at its source

- PMLiVE

AstraZeneca receives MHRA approval for Wainzua in rare nerve disease ATTRv-PN

The therapy is designed to reduce the effects of the disease by lowering the production of TTR protein

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links